PT -期刊文章盟莎拉Llufriu Gabilondo盟盟- Eloy Martinez-Heras盟奎利亚尔-尤兰达布兰科Morgado盟Fortea胡安盟卡莱斯猎鹰AU -玛丽亚赛盟Nuria Bargallo盟Nuria苍井空AU -巴勃罗Villoslada AU -弗朗西斯克格劳盟-阿尔伯特Saiz TI -认知能力和大脑的完整性在多发性硬化症:扩散张量成像研究(P06.112) DP - 2013年2月12日TA -神经病学PG - P06.112 P06.112 VI - 80 IP - 7补充4099 - //www.ez-admanager.com/content/80/7_Supplement/P06.112.short 4100 - //www.ez-admanager.com/content/80/7_Supplement/P06.112.full所以Neurolog首页y2013 2月12;80 AB -目的:我们旨在识别大脑区域微观结构损伤或病变与认知障碍在多发性硬化症(MS)。背景:断开的白质(WM)大片和灰质(GM)损伤可能与认知功能障碍在MS.DESIGN /方法:我们包括67 MS患者和37控制。认知评估病人的Rao电池通过z得分(正火)。结构T1-MPRAGE和所包含的核磁共振扩散张量成像(DTI)。Tract-based空间统计(tbs)和分布分析(VBA)被用来比较DTI值之间的病人和控制和本地化地区DTI分数各向异性(FA)或平均扩散系数(MD)水平与认知z分数正常WM女士(NAWM)和通用汽车在我们相关的z分数通过损伤与损伤可能性概率映射(行分钟)。结果:医学患者显示普遍减少NAWM FA和增加通用MD在几个地区。口头记忆与特定的大片中每一个分测验和地区病人女士:选择性提醒测试(SRT)长期储存与FA胼胝体(CC)、放射冠,后丘脑的辐射,矢状stratrum和扣带回和通用在左角,MD枕,舌、梭状回和颞叶皮层。NAWM SRT长期检索显示类似的发现,而相关性与通用MD是更广泛的(即。海马、左脑岛、角、枕叶和颞叶皮层)。SRT延迟回忆(DR)与足总在CC和MD左距状,舌、海马、丘脑和梭状皮层。视觉记忆与FA博士在CC和后丘脑的辐射。 The Symbol Digit Modalities Test showed widespread correlation with NAWM FA. LPM showed periventricular and corona radiata areas correlating with SRT long-term storage and DR.CONCLUSIONS: Both GM and WM microstructure have an influence on cognition that differs in different domains. We provide anatomic rendition of pathways implicated in the different processes of declarative verbal memory.Supported by: Partially funded by the Hospital Clinic Emili Letang grant and by the FIS PS09/00259 from the Instituto de Salud Carlos III (Spanish Ministry of Health).Disclosure: Dr. Llufriu has received personal compensation for activities with Merck Serono, Biogen Idec, Teva, and Novartis. Dr. Martinez-Heras has nothing to disclose. Dr. Gabilondo has nothing to disclose. Dr. Blanco Morgado has nothing to disclose. Dr. Fortea has received personal compensation for activities with Esteve and Novartis. Dr. Falcon has nothing to disclose. Dr. Sepulveda has nothing to disclose. Dr. Bargallo has nothing to disclose. Dr. Sola has nothing to disclose. Dr. Villoslada has received personal compensation for activities with Heidelberg Engineering, Novartis, Roche, Digna Biotech, Neurotec Pharma, and Bionure Pharma. Dr. Villoslada received research support from Novartis, Roche and Digna Biotech. Dr. Graus has nothing to disclose. Dr. Saiz has received personal compensation for activities with Bayer-Schering, Merck-Serono, Biogen Idec, Sanofi-Aventis, Teva Pharmaceutical Industries Ltd and Novartis as consultant and speaker.Thursday, March 21 2013, 7:30 am-12:00 pm